C-ITGTAeovian Pharmaceuticals
селективное ингибирование mTORC1, ингибирование CD38, малые молекулы
modulatingsmall molecule
Loading
Загрузка раздела...0-100 chain-logic scale · 15 dimensions · scored on public evidence
All companiesC-ITGT
C-ITGTC-ITGTселективное ингибирование mTORC1, ингибирование CD38, малые молекулы
0-100 chain-logic scale · 15 dimensions · scored on public evidence
Aeovian Pharmaceuticals селективное ингибирование mTORC1, ингибирование CD38, малые молекулы
Aeovian Pharmaceuticals — это biopharmaceutical company клинической стадии, разрабатывающая targeted и highly selective small molecules для восстановления cellular metabolic quality control. Ее ведущий кандидат в разработке, AV078, представляет собой first-in-class CNS-penetrant selective mTORC1 inhibitor для tuberous sclerosis complex refractory epilepsy. Компания также описывает proprietary library of small molecules, которые ингибируют либо mTORC1, либо CD38, для rare and age-related diseases.
The published score reflects a curated read of public evidence across 16 dimensions. Each dimension below shows the rationale we used. Disagree with a reading? Tell us where we are wrong
Higher up = higher Eternal Search score. Further right = closer to achieving real longevity outcomes (early mechanism → translational → near-term readout). Bubble size = capital deployed. Watch for MISMATCHES: big bubbles on the left are well-capitalized but far from goals; small bubbles on the right are doing more with less.
Aeovian Pharmaceuticals — Translational · Bottom quartile. Derived deterministically from 3 extracted project(s). Most-advanced status: phase 1. Band: translational. Aging-relevance not LLM-reviewed in this pass.
Source: Deterministic